Champions Oncology, Inc. (CSBR) Company Overview

Champions Oncology, Inc. is a Nasdaq-listed oncology research company that sits between a specialized contract research organization, a biological-model platform, and an emerging data business. Its core customers are pharmaceutical and biotechnology companies that need evidence about how experimental cancer therapies behave before or alongside clinical development. The company uses patient-derived xenograft models, ex vivo systems, bioanalytical assays, and computational tools to help customers test drug efficacy, explore combinations, identify biomarkers, and understand mechanisms of response or resistance. The official company site describes the business as an oncology CRO with preclinical and clinical specialty-testing capabilities.

What makes the platform different from a conventional CRO?

The central asset is a living TumorBank of clinically annotated patient-derived tumors. Champions expands selected tumors in mice, then adds molecular, phenotypic, pharmacologic, and clinical context. The fiscal 2025 Form 10-K reported roughly 3,500 molecular datasets, 3,000 clinical drug-response records, 3,500 in vivo drug responses, and about 20,000 public datasets integrated into its broader Datacenter. This means a customer can commission a study and also interrogate the associated data to decide which tumor subtype, biomarker, or combination strategy deserves further investment.

Which capabilities define the business today?

Champions earns most revenue through fixed-fee research studies. Signed statements of work become revenue as performance obligations are completed, usually within one year. Billing milestones, model readiness, amendments, and study timing can make quarterly revenue and cash flow diverge. Customers may terminate many contracts, but generally owe payment for work already performed.

Which revenue stream is largest?

Why is data licensing strategically important?

Data licenses have a different economic profile. Access is generally recognized when delivered, so one contract can create high-margin, point-in-time revenue. FY2025 included $4.7 million of TOS data-license revenue, including a $4.5 million first-time contract, while FY2024 had none. Pharmacology revenue was $48.6 million in FY2025 versus $47.0 million in FY2024. The strategic objective is repeatable monetization of data linked to living models, clinical annotation, drug response, and multi-omic characterization.

The freshest official reporting package is the Form 10-Q for the quarter ended January 31, 2026, supplemented by the company's fiscal 2026 third-quarter earnings release. The headline is that underlying study activity was strong, but the mix shifted away from the prior year's unusually large data-license transaction while outsourced radiolabeling and growth investments pressured margins.

What changed from the prior-year quarter?

Pharmacology services generated $16.2 million in Q3 FY2026, compared with $11.7 million in Q3 FY2025, while data-license revenue fell to zero from $4.5 million. Other TOS revenue declined to $0.4 million from $0.9 million. Management described study-service revenue as approximately 32% higher year over year and said previously delayed backlog converted during the quarter. However, more than $2.0 million of radiolabeling work was outsourced, helping drive cost of revenue to $8.8 million from $6.6 million and compressing the service margin to 47%.

What do the nine-month results say about earnings quality?

Champions' corporate history is unusually discontinuous. The legal entity began in 1985 around a sports-theme restaurant concept, then eventually became an oncology platform company. The useful history is not the legacy brand itself, but the sequence of strategic pivots that created today's mix of research services, data, and internally generated therapeutics. The fiscal 2025 Form 10-K provides the formal history and current strategy.

How did the model evolve from services toward data?

1. 1985-1997
   The company incorporated, completed a public offering, operated under a sports-theme restaurant identity, and later sold the concept. This period explains the legacy public shell but not the present economics.
2. 2007
   Management redirected the company toward biotechnology and acquired Biomerk, establishing the foundation for the current oncology-model business.
3. 2011
   The company adopted the Champions Oncology name, aligning the legal identity with personalized oncology drug development.
4. 2020
   Lumin launched as an oncology data-driven software program, creating a channel to monetize accumulated model and study data beyond project-based laboratory services.
5. 2021
   Champions expanded its strategy into drug discovery and development, using the Datacenter plus experimental validation to identify and advance therapeutic targets.
6. 2023
   The company formed Corellia AI as a wholly owned discovery subsidiary, reinforcing the ambition to convert data and models into proprietary therapeutic opportunities.
7. 2025
   Champions recorded its first large PDX data-license transaction, launched an expanded radiopharmaceutical platform after screening more than 30 models, and appointed Rob Brainin as CEO to emphasize data-enabled growth.
8. 2026
   Brian Alexander joined the board as the company deepened its data-driven oncology strategy, while eight AACR 2026 presentations highlighted response, resistance, KRAS, ADC, radiopharma, and CAR-T work.

Champions' competitive advantage is better described as a bundle of accumulated resources than as a single patent-protected moat. Its TumorBank is living, reusable, and increasingly annotated. That gives the company a practical advantage in matching a customer program to models that reflect clinically relevant tumor biology. The Datacenter then links those models to genomic, transcriptomic, proteomic, drug-response, and patient context. The company's company overview reports 1,400 highly characterized PDX models and 2,500 completed client studies.

Which resources are hardest to replicate?

Why does radiopharmaceutical capability matter?

Radiopharmaceutical research adds a growth modality that fits the existing platform. In July 2025 Champions announced a commercial launch after expanding its radioactive-materials license, completing radiochemistry infrastructure, and screening more than 30 PDX models. The official launch announcement listed ten supported isotopes and workflows spanning in vitro testing, ex vivo biodistribution, and therapeutic efficacy. Strategically, this can deepen wallet share with existing oncology customers; financially, the near-term challenge is to move radiolabeling in-house so outsourced costs do not erase the revenue benefit.

Champions does not present a fixed named competitor list in its latest 10-K, which is sensible because rivalry changes by study type. For a large outsourced preclinical program, it competes with larger CROs that have broader capacity and geographic scale. For a specialized PDX or ex vivo project, it competes with focused translational-model providers and academic laboratories. For Lumin and data licensing, the alternatives include scientific software vendors, public datasets, open-source analytics, and a customer's own bioinformatics team. In discovery therapeutics, the customer can also become a competitor because biopharma companies pursue internal targets and platform development.

What determines market position in this niche?

FY2025 showed that favorable study execution, data licensing, and cost discipline can produce profit and cash. Revenue reached $56.9 million, up 13.5%; operating income was $4.6 million versus a $7.4 million operating loss in FY2024; net income was $4.7 million; and operating cash flow was $7.4 million. With only $0.4 million of capital expenditure, a simple free-cash-flow proxy was about $7.0 million. The first nine months of FY2026 reversed part of that improvement as mix and outsourced work weakened margins.

What does the balance sheet support?

Champions reported no conventional funded-debt line at January 31, 2026, but lease obligations and negative working capital remain meaningful. Cash declined $2.7 million during the first nine months of FY2026 as operating cash flow was negative $2.5 million. Accounts receivable reached $12.1 million, while accounts payable plus accrued liabilities totaled $9.1 million. Management said existing cash and expected operating cash flow were adequate through at least March 2027, making bookings, billing, and cost control central liquidity variables.

Which cost lines matter most?

Champions has one vote per common share, but ownership is concentrated. The 2025 proxy statement reported 13.8 million shares outstanding on August 22, 2025 and directors and executive officers as a group beneficially owning 46.4%. That can align leaders with long-term value creation while giving a small group substantial influence over directors, compensation, financing, and strategic transactions.

Which holders have the most influence?

What changed in leadership?

Rob Brainin became CEO on August 25, 2025, while Ronnie Morris became chairman. Brainin’s genomics, diagnostics, and data-business background fits the shift toward data-enabled oncology R&D. Champions later appointed Tammer Farid to lead the data business and added Brian Alexander to the board in March 2026, reinforcing the emphasis on oncology, data science, and drug development.

The opportunity set is attractive because oncology development remains data-intensive, modality-rich, and expensive. Better preclinical decisions can save customers time and capital, especially in radiopharmaceuticals, antibody-drug conjugates, cell therapies, KRAS programs, and biomarker-driven combinations. Champions' eight AACR 2026 presentations covered response and resistance across several of these areas, reinforcing the scientific breadth described in the official AACR 2026 announcement.

Where could growth come from?

Which risks are most material?

What should researchers monitor next?

A DCF for Champions should not begin with a generic revenue-growth assumption. It should model the business as at least two economic engines: a laboratory-services base with capacity, utilization, and labor constraints; and a data/licensing opportunity with potentially higher margins but less predictable timing. Discovery therapeutics can be treated as option value unless a partnership, financing, or asset-specific milestone creates a clearer probability-weighted cash-flow path.

Which variables drive intrinsic value?